The phase I study of tazemetostat, which targets the PRC2 catalytic subunit EZH2 (NCT02601937), included paediatric patients with relapsed or refractory RTs, other SMARCB1-deficient tumours, and synovial sarcoma [77]. This evidence concerns the gene SMARCB1 and neoplasm.